Cargando…

Origin and Therapies of Osteosarcoma

SIMPLE SUMMARY: Osteosarcoma is the most common malignant bone tumor in children, with a 5-year survival rate ranging from 70% to 20% depending on the aggressiveness of the disease. The current treatments have not evolved over the past four decades due in part to the genetic complexity of the diseas...

Descripción completa

Detalles Bibliográficos
Autores principales: Moukengue, Brice, Lallier, Morgane, Marchandet, Louise, Baud’huin, Marc, Verrecchia, Franck, Ory, Benjamin, Lamoureux, Francois
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322921/
https://www.ncbi.nlm.nih.gov/pubmed/35884563
http://dx.doi.org/10.3390/cancers14143503
_version_ 1784756422951567360
author Moukengue, Brice
Lallier, Morgane
Marchandet, Louise
Baud’huin, Marc
Verrecchia, Franck
Ory, Benjamin
Lamoureux, Francois
author_facet Moukengue, Brice
Lallier, Morgane
Marchandet, Louise
Baud’huin, Marc
Verrecchia, Franck
Ory, Benjamin
Lamoureux, Francois
author_sort Moukengue, Brice
collection PubMed
description SIMPLE SUMMARY: Osteosarcoma is the most common malignant bone tumor in children, with a 5-year survival rate ranging from 70% to 20% depending on the aggressiveness of the disease. The current treatments have not evolved over the past four decades due in part to the genetic complexity of the disease and its heterogeneity. This review will summarize the current knowledge of OS origin, diagnosis and therapies. ABSTRACT: Osteosarcoma (OS) is the most frequent primary bone tumor, mainly affecting children and young adults. Despite therapeutic advances, the 5-year survival rate is 70% but drastically decreases to 20–30% for poor responders to therapies or for patients with metastasis. No real evolution of the survival rates has been observed for four decades, explained by poor knowledge of the origin, difficulties related to diagnosis and the lack of targeted therapies for this pediatric tumor. This review will describe a non-exhaustive overview of osteosarcoma disease from a clinical and biological point of view, describing the origin, diagnosis and therapies.
format Online
Article
Text
id pubmed-9322921
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93229212022-07-27 Origin and Therapies of Osteosarcoma Moukengue, Brice Lallier, Morgane Marchandet, Louise Baud’huin, Marc Verrecchia, Franck Ory, Benjamin Lamoureux, Francois Cancers (Basel) Review SIMPLE SUMMARY: Osteosarcoma is the most common malignant bone tumor in children, with a 5-year survival rate ranging from 70% to 20% depending on the aggressiveness of the disease. The current treatments have not evolved over the past four decades due in part to the genetic complexity of the disease and its heterogeneity. This review will summarize the current knowledge of OS origin, diagnosis and therapies. ABSTRACT: Osteosarcoma (OS) is the most frequent primary bone tumor, mainly affecting children and young adults. Despite therapeutic advances, the 5-year survival rate is 70% but drastically decreases to 20–30% for poor responders to therapies or for patients with metastasis. No real evolution of the survival rates has been observed for four decades, explained by poor knowledge of the origin, difficulties related to diagnosis and the lack of targeted therapies for this pediatric tumor. This review will describe a non-exhaustive overview of osteosarcoma disease from a clinical and biological point of view, describing the origin, diagnosis and therapies. MDPI 2022-07-19 /pmc/articles/PMC9322921/ /pubmed/35884563 http://dx.doi.org/10.3390/cancers14143503 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Moukengue, Brice
Lallier, Morgane
Marchandet, Louise
Baud’huin, Marc
Verrecchia, Franck
Ory, Benjamin
Lamoureux, Francois
Origin and Therapies of Osteosarcoma
title Origin and Therapies of Osteosarcoma
title_full Origin and Therapies of Osteosarcoma
title_fullStr Origin and Therapies of Osteosarcoma
title_full_unstemmed Origin and Therapies of Osteosarcoma
title_short Origin and Therapies of Osteosarcoma
title_sort origin and therapies of osteosarcoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322921/
https://www.ncbi.nlm.nih.gov/pubmed/35884563
http://dx.doi.org/10.3390/cancers14143503
work_keys_str_mv AT moukenguebrice originandtherapiesofosteosarcoma
AT lalliermorgane originandtherapiesofosteosarcoma
AT marchandetlouise originandtherapiesofosteosarcoma
AT baudhuinmarc originandtherapiesofosteosarcoma
AT verrecchiafranck originandtherapiesofosteosarcoma
AT orybenjamin originandtherapiesofosteosarcoma
AT lamoureuxfrancois originandtherapiesofosteosarcoma